Developing TRPV2 allosteric modulators for high unmet needs in Oncological and Cardiovascular pathologies.
TargTex is a pioneering biotechnology company dedicated to the development of innovative therapeutic approaches for life-threatening diseases. Our research programs span from Oncology to Cardiovascular indications, with a special emphasis on exploring the calcium channel TRPV2 as a novel therapeutic target.
TargTex’s lead program addresses a major unmet medical need, the most common and malignant brain tumor – Glioblastoma (GBM). TTX101 is a proprietary hydrogel formulation with a nanodispersed drug used as adjunct to surgery during the tumor excision, within the first step of standard of care. The small molecule nanonization enables a superior diffusion profile across the brain parenchyma to fully eliminate unresected tumor cells that lead to recurrence.
TTX101 has been granted Orphan Drug Designation by the FDA to treat malignant gliomas. Building on the same technology, the company is also developing new localized therapies applied to other solid tumors, including e.g. soft tissue sarcomas.
In the cardiovascular field, TargTex is developing a new series of small molecule TRPV2 antagonists for oral delivery, addressing a specific population with cardiomyopathies.
The multidisciplinary team is supported by seasoned experts bringing an amalgam of expertise in different areas of drug development. With a strong focus on TRPV2 and a promising lead candidate for Glioblastoma, the company’s R&D efforts are focused on leveraging TRPV2 allosteric modulation to create a pipeline of therapies that address high unmet medical needs, aiming to develop first-in-class new medicines that make a significant impact on patient’s lives and global health.
